Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:2671
Name transitional cell carcinoma
Definition A carcinoma that derives_from transitional epithelial cells.
Source DiseaseOntology.org
Alt Ids DOID:3995
Path disease disease of cellular proliferation cancer cell type cancer carcinoma transitional cell carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown PF-03446962 transitional cell carcinoma not applicable detail...
FGFR3 dec exp FGFR3 wild-type HRAS G12V AZ8010 transitional cell carcinoma decreased response detail...
FGFR3 dec exp FGFR3 wild-type HRAS G12V AZD4547 transitional cell carcinoma resistant detail...
FGFR3 S249C FGFR3 over exp PD173074 transitional cell carcinoma sensitive detail...
FGFR3 over exp AZD4547 transitional cell carcinoma sensitive detail...
FGFR3 over exp AZ8010 transitional cell carcinoma sensitive detail...
FGFR3 dec exp FGFR3 wild-type HRAS G12V PD173074 transitional cell carcinoma resistant detail...
FGFR3 - TACC3 Erdafitinib transitional cell carcinoma sensitive detail...
FGFR2 - BICC1 FGFR2 - CASP7 Erdafitinib transitional cell carcinoma predicted - sensitive detail...
Unknown unknown Docetaxel + Ramucirumab transitional cell carcinoma not applicable detail...
Unknown unknown Docetaxel + Icrucumab transitional cell carcinoma no benefit detail...
Unknown unknown Paclitaxel + Pazopanib transitional cell carcinoma not applicable detail...
Unknown unknown Atezolizumab transitional cell carcinoma not applicable detail...
FGFR3 - TACC3 Alpelisib + Infigratinib transitional cell carcinoma predicted - sensitive detail...
NRAS mutant Trametinib transitional cell carcinoma decreased response detail...
HRAS mutant Trametinib transitional cell carcinoma resistant detail...
ERBB2 positive lapuleucel-T transitional cell carcinoma no benefit detail...
Unknown unknown Cabozantinib transitional cell carcinoma not applicable detail...
FGFR3 mutant Infigratinib transitional cell carcinoma sensitive detail...
FGFR3 fusion Infigratinib transitional cell carcinoma sensitive detail...
Unknown unknown Domatinostat transitional cell carcinoma not applicable detail...
Unknown unknown Nivolumab transitional cell carcinoma not applicable detail...
Unknown unknown Everolimus transitional cell carcinoma not applicable detail...
Unknown unknown Durvalumab transitional cell carcinoma not applicable detail...
Unknown unknown Avelumab transitional cell carcinoma not applicable detail...
Unknown unknown Pembrolizumab transitional cell carcinoma not applicable detail...
FGFR3 - TACC3 AZD4547 + Buparlisib transitional cell carcinoma sensitive detail...
FGFR1 amp AZD4547 + Buparlisib transitional cell carcinoma sensitive detail...
FGFR3 - TACC3 AZD4547 transitional cell carcinoma predicted - sensitive detail...
FGFR3 mutant Docetaxel + Vofatamab transitional cell carcinoma predicted - sensitive detail...
FGFR3 fusion Docetaxel + Vofatamab transitional cell carcinoma predicted - sensitive detail...
FGFR1 mutant Erdafitinib transitional cell carcinoma predicted - sensitive detail...
FGFR2 mutant Erdafitinib transitional cell carcinoma sensitive detail...
FGFR3 mutant Erdafitinib transitional cell carcinoma sensitive detail...
FGFR3 V555L Infigratinib transitional cell carcinoma resistant detail...
FGFR3 V555M FGFR3 L608V Infigratinib transitional cell carcinoma resistant detail...
FGFR3 V555M Infigratinib transitional cell carcinoma resistant detail...
FGFR3 R248C Erdafitinib transitional cell carcinoma sensitive detail...
FGFR3 S249C Erdafitinib transitional cell carcinoma sensitive detail...
FGFR3 G370C Erdafitinib transitional cell carcinoma sensitive detail...
FGFR3 Y373C Erdafitinib transitional cell carcinoma sensitive detail...
FGFR3 - TACC3 Debio 1347 transitional cell carcinoma predicted - sensitive detail...
Unknown unknown MBG453 + Spartalizumab transitional cell carcinoma not applicable detail...
Unknown unknown Toripalimab transitional cell carcinoma not applicable detail...
FGFR3 mutant Nivolumab transitional cell carcinoma no benefit detail...
FGFR3 mutant Atezolizumab transitional cell carcinoma no benefit detail...
FGFR3 fusion Erdafitinib transitional cell carcinoma predicted - sensitive detail...
FGFR2 fusion Erdafitinib transitional cell carcinoma predicted - sensitive detail...
Unknown unknown Enfortumab vedotin-ejfv transitional cell carcinoma not applicable detail...
Unknown unknown Lenvatinib + Pembrolizumab transitional cell carcinoma not applicable detail...
HRAS act mut Tipifarnib transitional cell carcinoma predicted - sensitive detail...
HRAS mutant Tipifarnib transitional cell carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00978250 Phase II 5-Fluoro-2-deoxycytidine + Tetrahydrouridine A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) Completed
NCT01004224 Phase I Infigratinib A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies Completed
NCT01920061 Phase I Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) Recruiting
NCT02052778 Phase Ib/II Futibatinib A Study of TAS-120 in Patients With Advanced Solid Tumors Active, not recruiting
NCT02393248 Phase Ib/II Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib INCMGA00012 + Pemigatinib Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Recruiting
NCT02501096 Phase Ib/II Pembrolizumab Lenvatinib Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors Active, not recruiting
NCT02516241 Phase III Durvalumab + Tremelimumab Carboplatin + Cisplatin + Gemcitabine Durvalumab Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer Active, not recruiting
NCT02573259 Phase I PF-06801591 A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors Active, not recruiting
NCT02599324 Phase Ib/II Cetuximab + Ibrutinib Ibrutinib + Paclitaxel Everolimus + Ibrutinib Docetaxel + Ibrutinib A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Recruiting
NCT02603432 Phase III Avelumab A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) Active, not recruiting
NCT02628535 Phase I MGD009 Safety Study of MGD009 in B7-H3-expressing Tumors Terminated
NCT02660034 Phase I Pamiparib + Tislelizumab The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors Active, not recruiting
NCT02717156 Phase II Pembrolizumab + sEphB4-HSA Recombinant EphB4-HSA Fusion Protein and Pembrolizumab in Treating Patients With Metastatic or Recurrent Urothelial Cancer That Is Refractory to Certain Chemotherapy Drugs Recruiting
NCT02795156 Phase II Cabozantinib Afatinib Regorafenib Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Recruiting
NCT02807636 Phase III Atezolizumab + Carboplatin + Gemcitabine Carboplatin + Gemcitabine The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy Active, not recruiting
NCT02812420 Phase I Durvalumab + Tremelimumab Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy Active, not recruiting
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting
NCT02872714 Phase II Pemigatinib A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) Recruiting
NCT02880345 Phase 0 Pembrolizumab RADVAX: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy Withdrawn
NCT03018405 Phase I NKR-2 cells A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) Recruiting
NCT03029832 Phase II Atezolizumab Atezolizumab + MOXR0916 A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy Terminated
NCT03036098 Phase III Cisplatin + Gemcitabine Ipilimumab + Nivolumab Carboplatin + Gemcitabine Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care Chemotherapy in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer Recruiting
NCT03047213 Phase II Sapanisertib Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations Recruiting
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Unknown status
NCT03091660 Phase III BCG Tokyo-172 Strain Solution BCG solution Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer Recruiting
NCT03115801 Phase II Atezolizumab Nivolumab A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers Active, not recruiting
NCT03123055 Phase I Atezolizumab + Vofatamab A Study of B-701 in Combination With Atezolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (U22) Terminated
NCT03179943 Phase II Atezolizumab + Guadecitabine Overcoming Chechkpoint Inhibitor Resistance With Epigenetic Therapy in Urothelial Cancer Suspended
NCT03207867 Phase II PBF-509 + Spartalizumab A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma Recruiting
NCT03208712 Phase I Atezolizumab + Radium Ra 223 dichloride Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy Terminated
NCT03219333 Phase II Enfortumab vedotin-ejfv A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201) Active, not recruiting
NCT03236935 Phase I L-NMMA + Pembrolizumab Phase Ib of L-NMMA and Pembrolizumab Recruiting
NCT03240016 Phase II Nab-paclitaxel + Pembrolizumab Abraxane With Anti-PD1/PDL1 in Cisplatin-ineligible Patients With Advanced Urothelial Cancer Recruiting
NCT03241173 Phase Ib/II INCAGN01949 + Ipilimumab INCAGN01949 + Nivolumab INCAGN01949 + Ipilimumab + Nivolumab A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies Completed
NCT03264066 Phase II Atezolizumab + Cabozantinib A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors Active, not recruiting
NCT03277352 Phase Ib/II Epacadostat + INCAGN01876 + Pembrolizumab INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies Active, not recruiting
NCT03287050 Phase I Pembrolizumab Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma Active, not recruiting
NCT03288545 Phase I Atezolizumab + Enfortumab vedotin-ejfv + Pembrolizumab A Safety Study of Enfortumab Vedotin Plus Immune Checkpoint Inhibitor Therapy for Patients With Urothelial Bladder Cancer (EV-103) Recruiting
NCT03289962 Phase I RO7198457 Atezolizumab + RO7198457 A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors Recruiting
NCT03311334 Phase I Atezolizumab + DSP-7888 DSP-7888 + Nivolumab A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors Recruiting
NCT03317496 Phase II Avelumab + Cisplatin + Gemcitabine Avelumab + Carboplatin + Pemetrexed Disodium Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies Recruiting
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Recruiting
NCT03330405 Phase II Avelumab + Talazoparib Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors Active, not recruiting
NCT03343613 Phase I LY3300054 + LY3381916 LY3381916 A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors Terminated
NCT03361228 Phase Ib/II Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors Terminated
NCT03363776 Phase Ib/II BMS-986277 BMS-986277 + Nivolumab An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers Active, not recruiting
NCT03375307 Phase II Olaparib Olaparib in Treating Patients With Metastatic or Advanced Urothelial Cancer With DNA-Repair Defects Recruiting
NCT03390504 Phase III Pembrolizumab Erdafitinib Docetaxel + Vinflunine A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations Recruiting
NCT03407976 Phase Ib/II Apatinib + Pembrolizumab Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies Active, not recruiting
NCT03409458 Phase Ib/II Avelumab + Imifoplatin A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1) Recruiting
NCT03410927 Phase Ib/II TAS0728 A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities Active, not recruiting
NCT03416335 Phase Ib/II DSP-0509 DSP-0509 + Pembrolizumab A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile Recruiting
NCT03419130 Phase II Pembrolizumab Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer Withdrawn
NCT03435640 Phase Ib/II NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies Recruiting
NCT03448718 Phase II Olaparib Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations Recruiting
NCT03449381 Phase I BI 907828 This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors) Recruiting
NCT03451331 Phase II Carboplatin + Gemcitabine + Nivolumab Gemcitabine + Nivolumab + Oxaliplatin Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer Recruiting
NCT03472560 Phase II Avelumab + Axitinib A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF) Active, not recruiting
NCT03473743 Phase Ib/II Erdafitinib + JNJ-63723283 A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene Alterations Recruiting
NCT03474107 Phase III Enfortumab vedotin-ejfv Docetaxel + Paclitaxel + Vinflunine A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) Active, not recruiting
NCT03486197 Phase II Pembrolizumab Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma Recruiting
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Recruiting
NCT03523572 Phase I Nivolumab + Trastuzumab deruxtecan Trastuzumab Deruxtecan (DS-8201a) With Nivolumab in Advanced Breast and Urothelial Cancer Recruiting
NCT03525795 Phase Ib/II CPI-1205 + Ipilimumab ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors Active, not recruiting
NCT03528694 Phase III BCG solution + Durvalumab BCG solution Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer Recruiting
NCT03534804 Phase II Cabozantinib + Pembrolizumab Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab) Recruiting
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Recruiting
NCT03547973 Phase II Sacituzumab govitecan-hziy Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer Recruiting
NCT03590054 Phase I Abexinostat + Pembrolizumab A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies Recruiting
NCT03606174 Phase II MGCD516 + Nivolumab Sitravatinib and Nivolumab in Urothelial Carcinoma Study Recruiting
NCT03621982 Phase I Camidanlumab Tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Recruiting
NCT03633110 Phase Ib/II GEN-009 GEN-009 + Nivolumab Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine Active, not recruiting
NCT03639714 Phase Ib/II GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab A Study of a Personalized Neoantigen Cancer Vaccine Recruiting
NCT03666273 Phase I BAY1905254 BAY1905254 + Pembrolizumab A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254 Recruiting
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Recruiting
NCT03679767 Phase II INCMGA00012 A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) Recruiting
NCT03682289 Phase II AZD6738 + Olaparib Olaparib Phase II Trial of AZD6738 Alone and in Combination With Olaparib Recruiting
NCT03693612 Phase Ib/II GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors Recruiting
NCT03744793 Phase II Avelumab + Pemetrexed Disodium Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer Recruiting
NCT03752398 Phase I XmAb23104 A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) Recruiting
NCT03758781 Phase I Cyclophosphamide + IRX-2 + Nivolumab IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors Recruiting
NCT03785925 Phase II Nivolumab + NKTR-214 Carboplatin + Gemcitabine A Randomized Study of NKTR-214 Plus Nivolumab and of Reference Chemotherapy in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer With Low PD-L1 Expression (PIVOT-10) Recruiting
NCT03809624 Phase I INBRX-105 Study of INBRX-105 in Patients With Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma (PDL1x41BB) Recruiting
NCT03836352 Phase II DPX-Survivac + Pembrolizumab Cyclophosphamide + DPX-Survivac + Pembrolizumab Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors Recruiting
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Recruiting
NCT03854474 Phase Ib/II Pembrolizumab + Tazemetostat Tazemetostat and Pembrolizumab in Treating Patients With Locally Advanced or Metastatic Urothelial Carcinoma Recruiting
NCT03894618 Phase I SL-279252 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Recruiting
NCT03915405 Phase I Avelumab + KHK2455 KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer Recruiting
NCT03917381 Phase Ib/II GEN1046 GEN1046 Safety Trial in Patients With Malignant Solid Tumors Recruiting
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Active, not recruiting
NCT03970382 Phase I NeoTCR-P1 T-cells + Nivolumab NeoTCR-P1 T-cells A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors Recruiting
NCT03973333 Phase Ib/II Atezolizumab + IMC-C103C IMC-C103C Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab Recruiting
NCT03989362 Phase II Ipilimumab + Vopratelimab Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer (EMERGE) Recruiting
NCT03992131 Phase Ib/II Lucitanib + Rucaparib Rucaparib + Sacituzumab govitecan-hziy A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR) Recruiting
NCT04003610 Phase II Pembrolizumab + Pemigatinib Pembrolizumab Carboplatin + Gemcitabine Pemigatinib Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) Recruiting
NCT04007744 Phase I Pembrolizumab + Sonidegib Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors Recruiting
NCT04044859 Phase I ADP-A2M4 cells Surpass: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Tumors Recruiting
NCT04095273 Phase I BAY1895344 + Pembrolizumab Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Recruiting
NCT04096638 Phase I Nivolumab + SB 11285 SB 11285 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting
NCT04114136 Phase II Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies Not yet recruiting
NCT04149574 Phase III BCG solution + Nivolumab BCG solution A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8) Recruiting
NCT04152018 Phase I PF-06801591 + PF-06940434 PF-06940434 Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. Recruiting
NCT04158700 Phase Ib/II LY3200882 + Pembrolizumab A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer Withdrawn
NCT04173338 Phase I Cabozantinib + Pemetrexed Disodium Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma Recruiting
NCT04198766 Phase I INBRX-106 INBRX-106 + Pembrolizumab Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Recruiting
NCT04200963 Phase I KYN-175 KYN-175 in Patients With Advanced or Metastatic Solid Tumors and Urothelial Carcinoma Recruiting
NCT04223856 Phase III Carboplatin + Enfortumab vedotin-ejfv + Pembrolizumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Enfortumab vedotin-ejfv + Pembrolizumab Cisplatin + Enfortumab vedotin-ejfv + Pembrolizumab Enfortumab Vedotin and Pembrolizumab, With or Without Chemotherapy, vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302) Recruiting
NCT04259450 Phase Ib/II AFM24 Study to Assess AFM24 in Advanced Solid Cancers Recruiting
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Not yet recruiting
NCT04311710 Phase Ib/II Ipilimumab + Nivolumab Ipilimumab + Nivolumab + rHuPH20 A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U) Recruiting
NCT04322643 Phase II Durvalumab Pembrolizumab Avelumab Nivolumab Atezolizumab Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma Recruiting
NCT04388852 Phase I DS-3201b + Ipilimumab DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers Not yet recruiting
NCT04423029 Phase Ib/II DF6002 + Pembrolizumab DF6002 Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications Not yet recruiting
NCT04434560 Phase II Ipilimumab + Nivolumab Neoadjuvant Immunotherapy in Brain Metastases Not yet recruiting
NCT04452214 Phase I A Study of the Safety and Tolerance of CAN04 in Combination With Pembrolizumab in Subjects With Solid Tumors Not yet recruiting